Search
forLearn
5 / 801 resultslearn KY19382
compound that activates Wnt/β-catenin to promote hair regrowth and create new hair follicles
learn SCUBE3
a signaling molecule from dermal papilla cells being actively researched
learn Follistatin
glycoprotein that inhibits TGF-β and promotes hair growth by antagonizing activin
learn oligopeptide-71
Research
5 / 10 results
research A volatile producing Bacillus subtilis strain from the rhizosphere of Haloxylon ammodendron promotes plant root development
The conclusion is that certain chemicals from Bacillus subtilis help improve plant root growth through a hormone-related process.
research The CLE40 and CRN/CLV2 Signaling Pathways Antagonistically Control Root Meristem Growth in Arabidopsis
CLE40 and CRN/CLV2 pathways have opposite effects on root growth in Arabidopsis.
research A volatile producing Bacillus subtilis strain from the rhizosphere of Haloxylon ammodendron promotes plant root development
Bacillus subtilis strain WM13-24 helps plant root growth through volatile compounds.
research Auxin and ethylene: collaborators or competitors?
Auxin and ethylene hormones both work together and against each other to control plant growth.
research Integration of Ethylene and Auxin Signaling and the Developmental Consequences of Their Crosstalk
Ethylene and auxin hormones interact in complex ways that are essential for plant growth and development.
Community Join
5 / 1000+ resultscommunity Expectations control for SCUBE3
SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.
community Why was this compound abandoned ?
KY19382, a promising compound for hair loss, is not widely discussed or used. One user is currently testing it and plans to share results in a few weeks.
community The story of RU58841/PSK3841
RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.
community FCE 28260: A Forgotten 5α-Reductase Inhibitor
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
community Selling KY19382 powder a novel activator of Wnt/β-catenin signaling Product
Selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. KY19382 is a growth agonist.